Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples.

Autor: Ho-Pun-Cheung A; ICM, Institut régional du Cancer de Montpellier, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France., Bazin H; CisBio SA, Codolet, France., Boissière-Michot F; ICM, Institut régional du Cancer de Montpellier, Montpellier, France., Mollevi C; ICM, Institut régional du Cancer de Montpellier, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France., Simony-Lafontaine J; ICM, Institut régional du Cancer de Montpellier, Montpellier, France., Landas E; CisBio SA, Codolet, France., Bleuse JP; ICM, Institut régional du Cancer de Montpellier, Montpellier, France., Chardès T; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France., Prost JF; GamaMabs Pharma SA, Centre Pierre Potier, Toulouse, France., Pèlegrin A; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France., Jacot W; ICM, Institut régional du Cancer de Montpellier, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France., Mathis G; CisBio SA, Codolet, France., Lopez-Crapez E; ICM, Institut régional du Cancer de Montpellier, Montpellier, France. evelyne.crapez@icm.unicancer.fr.; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France. evelyne.crapez@icm.unicancer.fr.
Jazyk: angličtina
Zdroj: British journal of cancer [Br J Cancer] 2020 Feb; Vol. 122 (3), pp. 397-404. Date of Electronic Publication: 2019 Dec 03.
DOI: 10.1038/s41416-019-0670-8
Abstrakt: Background: Triple-negative breast cancer (TNBC) has a worse prognosis compared with other breast cancer subtypes, and biomarkers to identify patients at high risk of recurrence are needed. Here, we investigated the expression of human epidermal receptor (HER) family members in TNBC and evaluated their potential as biomarkers of recurrence.
Methods: We developed Time Resolved-Förster Resonance Energy Transfer (TR-FRET) assays to quantify HER1, HER2 and HER3 in formalin-fixed paraffin-embedded (FFPE) tumour tissues. After assessing the performance and precision of our assays, we quantified HER protein expression in 51 TNBC specimens, and investigated the association of their expression with relapse-free survival.
Results: The assays were quantitative, accurate, and robust. In TNBC specimens, HER1 levels ranged from ≈4000 to more than 2 million receptors per cell, whereas HER2 levels varied from ≈1000 to 60,000 receptors per cell. HER3 expression was very low (less than 5500 receptors per cell in all samples). Moderate HER2 expression was significantly associated with higher risk of recurrence (HR = 3.93; P = 0.003).
Conclusions: Our TR-FRET assays accurately quantify HER1, HER2 and HER3 in FFPE breast tumour specimens. Moderate HER2 expression may represent a novel prognostic marker in patients with TNBC.
Databáze: MEDLINE
Externí odkaz: